Fungal pneumonia
| Fungal pneumonia | |
|---|---|
|
| |
| Classification and external resources |
Fungal pneumonia is an infection of the lungs by fungi. It can be caused by either endemic or opportunistic fungi or a combination of both. Case mortality in fungal pneumonias can be as high as 90% in immunocompromised patients,[1][2] though immunocompetent patients generally respond well to anti-fungal therapy.
Causes
Specific instances of fungal infections that can manifest with pulmonary involvement include:
- histoplasmosis, which has primary pulmonary lesions and hematogenous dissemination
- coccidioidomycosis, which begins with an often self-limited respiratory infection (also called "Valley fever" or "San Joaquin fever")
- pulmonary blastomycosis
- pneumocystis pneumonia, which typically occurs in immunocompromised people, especially AIDS
- sporotrichosis — primarily a lymphocutaneous disease, but can involve the lungs as well
- cryptococcosis — contracted through inhalation of soil contaminated with the yeast, it can manifest as a pulmonary infection and as a disseminated one
- aspergillosis, resulting in invasive pulmonary aspergillosis
- rarely, candidiasis has pulmonary manifestations in immunocompromised patients.
- Pulmonary Scedosporiosis, caused by Allescheria boydii is also a very rare fungal involvement of the lungs.[3]
Pathophysiology
Fungi typically enter the lung with inhalation of their spores, though they can reach the lung through the bloodstream if other parts of the body are infected. Also, fungal pneumonia can be caused by reactivation of a latent infection. Once inside the alveoli, fungi travel into the spaces between the cells and also between adjacent alveoli through connecting pores. This invasion triggers the immune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophils) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system. This results in the fever, chills, and fatigue common in bacterial and fungal pneumonia. The neutrophils and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.
Diagnosis
Fungal pneumonia can be diagnosed in a number of ways. The simplest and cheapest method is to culture the fungus from a patient's respiratory fluids. However, such tests are not only insensitive but take time to develop which is a major drawback because studies have shown that slow diagnosis of fungal pneumonia is linked to high mortality.[4] Microscopy is another method but is also slow and imprecise. Supplementing these classical methods is the detection of antigens. This technique is significantly faster but can be less sensitive and specific than the classical methods.[5]
A molecular test based on quantitative PCR is also available from Myconostica. Relying on DNA detection, this is the most sensitive and specific test available for fungi but it is limited to detecting only pneumocystis jirovecii and aspergillus.[6]
Treatment
Fungal pneumonia can be treated with antifungal drugs and sometimes by surgical debridement.
See also
- Pneumonia
- Medusoid Mycelium
Notes and references
- ↑ Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (July 2007). "Invasive aspergillosis in the intensive care unit". Clin. Infect. Dis. 45 (2): 205–16. doi:10.1086/518852. PMID 17578780.
- ↑ Bulpa P, Dive A, Sibille Y (October 2007). "Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease". Eur. Respir. J. 30 (4): 782–800. doi:10.1183/09031936.00062206. PMID 17906086.
- ↑ Meshram, Sushant; Mishra Gyanshankar (December 2011). "Pulmonary scedosporiosis–A rare entity" (PDF). Asian Pacific Journal of Tropical Disease. 1 (4): 330–332. doi:10.1016/S2222-1808(11)60076-5. Retrieved 14 February 2013.
- ↑ Morrell M, Fraser VJ, Kollef MH (September 2005). "Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality". Antimicrob. Agents Chemother. 49 (9): 3640–5. doi:10.1128/AAC.49.9.3640-3645.2005. PMC 1195428
. PMID 16127033. - ↑ Denning, D (September 2008). "Webinar on fungal diagnostics" (PDF).
- ↑ , Philippe Hauser, Lagrou K, Cui X, PerlinD S, Park S, Harrison E, Meerssman W, Hughes M J, Bowyer P, Denning DW, Bille J, Lass-Flor C, Maertens J. Clinical performance of FXG : RESP (Asp +) assay for Aspergillus spp. and Pneumocystis jirovecii on respiratory specimens. Unpublished Data.